KDx Diagnostics Announces CE Marking for Innovative Non-invasive URO17™ Bladder Cancer Test

KDx Diagnostics, Inc., announced today that it has received Conformité Européene (CE) Marking for its innovative and proprietary urine-based test (the URO17™ test) for bladder cancer... more


KDx Diagnostics announces FDA Breakthrough Device designation for URO17™, Innovative urine test 

CAMPBELL, Calif., Jan. 8, 2020 /PRNewswire/ -- KDx Diagnostics, Inc. (KDx), announced today that the Food and Drug Administration (FDA) has granted "Breakthrough Device" designation for its URO17™ Bladder Cancer Recurrence Test... more


Demonstration of Keratin 17 Biomarker for Urothelial Carcinoma Detection

Bladder carcinoma is a common urological cancer with high morbidity, mortality, and recurrence rates requiring frequent, invasive diagnostic procedures...more(1) more(2) 


A Better Future 

A new biomarker allows effective, noninvasive screening of patients at risk of the disease. Bladder cancer presents a diagnostic challenge for even the best pathologists and laboratory medicine professionals...more


Acupath First Commercial Lab to Offer URO17™, Innovative New Biomarker

PLAINVIEW, N.Y. and CAMPBELL, Calif., July 25, 2019 /PRNewswire/ -- Acupath Laboratories, Inc., a leading provider of sub-specialized anatomic and molecular pathology services, and KDx Diagnostics, Inc., a leading developer of bladder cancer tests, today announced that KDx has licensed Acupath to incorporate its URO17™ ...more


Validation of a Novel Cytologic Biomarker for Urothelial Carcinoma

and cystoscopy have limited sensitivity and specificity for the diagnosis of urothelial carcinoma ( due to inflammatory atypia, sampling errors, and other clinicopathologic factors that may...more


Keratin 17 is a Sensitive and Specific Biomarker of Urothelial Neoplasia

The current study aimed to evaluate keratin 17 (K17), an oncoprotein that drives cell cycle progression in cancers of multiple anatomic sites as a diagnostic biomarker of urothelial neoplasia in bladder biopsies and in urine cytology specimens...more


Keratin 17 is a sensitive and specific biomarker of urothelial

There is a clinical need to identify novel biomarkers to improve diagnostic accuracy for the detection of urothelial tumors.
The current study aimed to evaluate keratin 17 (K17), an oncoprotein that drives cell cycle progression in cancers...more

EAU'20 ( Cancelled Event Due to COVID-19)

 The biggest urological event in Europe


LUGPA is the only nonprofit urology trade association in the US.


A non-profit organization (501 c6) composed of Urologists and Urology professionals joining together to further their mission.


The American Association for Cancer Research

Copyright © All Rights Reserved

LEGAL NOTICE; By accessing, browsing and/or otherwise using this website, you acknowledge that you have read, understood, and are bound by the KDx Diagnostics Inc. Website Terms and Conditions, and Privacy Policy and shall comply with all applicable laws and regulations. If you do not agree to these terms, do not use this website. Additionally, this website contains information on products that is targeted to many different audiences and may contain product details or information otherwise not accessible or valid in your country. Please be aware that KDx Diagnostics Inc. does not take any responsibility for your decision to access any such information on this website that may not comply with a legal process, regulation, registration or usage in the country of your origin.

Website Creator: Chelgis Jahanfard